The estimated Net Worth of Andrew P Rasdal is at least $815 Tysiąc dollars as of 6 August 2019. Mr. Rasdal owns over 12,500 units of Obalon Therapeutics Inc stock worth over $215,761 and over the last 19 years he sold OBLN stock worth over $0. In addition, he makes $598,794 as Chairman of the Board, President oraz Chief Executive Officer at Obalon Therapeutics Inc.
Andrew has made over 1 trades of the Obalon Therapeutics Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he bought 12,500 units of OBLN stock worth $50,000 on 6 August 2019.
The largest trade he's ever made was buying 12,500 units of Obalon Therapeutics Inc stock on 6 August 2019 worth over $50,000. On average, Andrew trades about 1,136 units every 0 days since 2005. As of 6 August 2019 he still owns at least 77,892 units of Obalon Therapeutics Inc stock.
You can see the complete history of Mr. Rasdal stock trades at the bottom of the page.
Andrew P. Rasdal has been appointed as Chairman of the Board, President, Chief Executive Officer of the Company effective 6/29/2020. He is no longer serves as Chief Executive Officer, Director of the Company effective as of January 2, 2019. Previously, Mr. Rasdal was the President and Chief Executive Officer at DexCom, Inc., a medical device company, from January 2002 until June 2007. Prior to DexCom, Mr. Rasdal served as President of Vascular and Senior Vice President for Medtronic, Inc., a medical technology development company, from 1999 to 2002. Prior to Medtronic, Mr. Rasdal served as Vice President of Marketing at Arterial Vascular Engineering, Inc., or AVE (acquired by Medtronic), a coronary stent company, from 1997 to 1999. Mr. Rasdal has also served in various senior positions at EP Technologies, Inc., SCIMED Life Systems, Inc. and Advanced Cardiovascular Systems, Inc. Mr. Rasdal holds a B.S. from San Jose State University and an M.M. from the Kellogg School of Management at Northwestern University.
As the Chairman of the Board, President oraz Chief Executive Officer of Obalon Therapeutics Inc, the total compensation of Andrew Rasdal at Obalon Therapeutics Inc is $598,794. There are 1 executives at Obalon Therapeutics Inc getting paid more, with Dr. Kelly Huang Ph.D. having the highest compensation of $800,112.
Andrew Rasdal is 60, he's been the Chairman of the Board, President oraz Chief Executive Officer of Obalon Therapeutics Inc since 2020. There are 5 older and 8 younger executives at Obalon Therapeutics Inc. The oldest executive at Obalon Therapeutics Inc is Raymond Dittamore, 73, who is the Independent Director.
Andrew's mailing address filed with the SEC is 5421 Avenida Encinas f, Carlsbad, CA 92008, USA.
Over the last 8 years, insiders at Obalon Therapeutics Inc have traded over $0 worth of Obalon Therapeutics Inc stock and bought 3,260,355 units worth $6,939,913 . The most active insiders traders include Parters Vii L Pblair James ..., Partners X Lp Inter West Ma... oraz David Moatazedi. On average, Obalon Therapeutics Inc executives and independent directors trade stock every 54 days with the average trade being worth of $432,771. The most recent stock trade was executed by William J. Plovanic on 12 November 2019, trading 65,000 units of OBLN stock currently worth $107,900.
Obalon Therapeutics, Inc. is a San Diego-based company focused on developing and commercializing novel technologies for weight loss.
Obalon Therapeutics Inc executives and other stock owners filed with the SEC include: